on objective measures of cognition, subtle cognitive changes that have been associated with this stage of disease remain poorly understood (Dubois et al., 2014) .
Another model of preclinical AD has recently been proposed in the context of a cross-sectional study that assessed a populationbased sample of 985 CN people aged (Jack et al., 2014) . However, the neurodegenerative status in this study was determined based on topographical biomarkers of AD, more specifically by an AD signature 18 F-fluorodeoxyglucose ( 18 F-FDG) PET and hippocampal volume on MRI. These topographical markers are not unique markers of Alzheimer's pathology; for example, hippocampal volume is reduced in other conditions, such as frontotemporal dementia, hippocampal sclerosis, Lewy-related pathology, argyrophilic grain disease, diabetes, and bipolar disorder, among others (Jack et al., 2012; Dubois et al., 2014) . Thus, although these findings still suggest that pathological aging is a predominant way of cognitive aging, they also indicate a need for consensus on which biomarkers are suggestive of Alzheimer's pathology only and thus better suited for untangling preclinical AD and the healthy brain aging.
As models of preclinical AD continue to develop, a challenge to the field is to reconcile the evidence of AD-related pathology found in a large number of CN elderly people (Jack et al., 2012 (Jack et al., , 2014 with the notion of "healthy" or "successful" aging (Rowe and Kahn, 1987) . This evidence seems to question the research practice of not considering possible presence of Alzheimer's pathology in CN elderly participants when including healthy elderly persons in cognitive studies. However, without the actual evidence to exclude Alzheimer's pathology, one can assume that some percentage of CN elderly subjects in such studies may represent preclinical AD. This problem has been occasionally recognized (Gold et al., 2013; Brier et al., 2014) . It clearly requires a systematic change in approach, because subtle cognitive changes, reliance on cognitive strategies, and networks' reorganization that one would interpret as the effects of healthy aging might actually reflect the disease progression. While the number of studies investigating that the impact of atrophy, hypometabolism, white matter changes, and ApoE4 on cognitive processes across the AD stages is consistently growing, possible effects of β-amyloid, t-tau, and p-tau on cognitive processes in preclinical AD remain largely unexplored (Riedel, 2014) .
Finally, in addition to apparently small percentage of CN persons who despite an advanced age resist Alzheimer's pathology (Jack et al., 2012 (Jack et al., , 2014 , there exist so-called SuperAgers. These are elderly people (80+) who appear to have healthy brains and well-preserved memory abilities. A recent study involving 12 SuperAgers found that their memory abilities were comparable to those of a group of healthy 50-and 65-year-old persons. When compared to a group of healthy age-matched peers on measures of cortical thickness, the SuperAgers had significantly thicker cerebral cortex. Furthermore, the left anterior cingulate was significantly thicker in SuperAgers compared to both groups (Harrison et al., 2012) . Thus, we find not only neuropathology but also healthy brains and preserved memory at well-advanced age.
In conclusion, it is now possible to establish the presence/absence of Alzheimer's pathology in vivo by measuring parameters that indicate biological changes caused by AD, thereby determining if a person is at risk for developing AD. Incorporating such evidence into cognitive aging research allows a differentiation of possible influences of Alzheimer's pathology from the effects of healthy aging on cognitive processes. Only by systematically incorporating such evidence in research on cognitive aging, we will be able to make a progress in disentangling preclinical AD from healthy cognitive aging.
